Toxicity and Pharmacokinetic Profile for Single-Dose Injection of ABY-029: a Fluorescent Anti-EGFR Synthetic Affibody Molecule for Human Use

PurposeABY-029, a synthetic Affibody peptide, Z03115-Cys, labeled with a near-infrared fluorophore, IRDye® 800CW, targeting epidermal growth factor receptor (EGFR) has been produced under good manufacturing practices for a US Food and Drug Administration-approved first-in-use human study during surgical resection of glioma, as well as other tumors. Here, the pharmacology, phototoxicity, receptor activity, and biodistribution studies of ABY-029 were completed in rats, prior to the intended human use.ProceduresMale and female Sprague Dawley rats were administered a single intravenous dose of varying concentrations (0, 245, 2449, and 24,490 μg/kg corresponding to 10×, 100×, and 1000× an equivalent human microdose level) of ABY-029 and observed for up to 14 days. Histopathological assessment of organs and tissues, clinical chemistry, and hematology were performed. In addition, pharmacokinetic clearance and biodistribution of ABY-029 were studied in subgroups of the animals. Phototoxicity and ABY-029 binding to human and rat EGFR were assessed in cell culture and on immobilized receptors, respectively.ResultsHistopathological assessment and hematological and clinical chemistry analysis demonstrated that single-dose ABY-029 produced no pathological evidence of toxicity at any dose level. No phototoxicity was observed in EGFR-positive and EGFR-negative glioma cell lines. Binding strength and pharmacokinetics of the anti-EGFR Affibody molecules were retained after labeling with the dye.ConclusionBased on the successful safety profile of ABY-029, the 1000× human microdose 24.5 mg/kg was identified as the no observed adverse effect level following intravenous administration. Conserved binding strength and no observed light toxicity also demonstrated ABY-029 safety for human use.

[1]  Nihal Ahmad,et al.  Dose translation from animal to human studies revisited , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[2]  Tristan Barrett,et al.  In vivo Diagnosis of Epidermal Growth Factor Receptor Expression using Molecular Imaging with a Cocktail of Optically Labeled Monoclonal Antibodies , 2007, Clinical Cancer Research.

[3]  W. Stummer,et al.  Technical Principles for Protoporphyrin-IX-Fluorescence Guided Microsurgical Resection of Malignant Glioma Tissue , 1998, Acta Neurochirurgica.

[4]  M. Lubberink,et al.  Biodistribution and Radiation Dosimetry of the Anti-HER2 Affibody Molecule 68Ga-ABY-025 in Breast Cancer Patients , 2016, The Journal of Nuclear Medicine.

[5]  F. Zanella,et al.  Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. , 2006, The Lancet. Oncology.

[6]  Joachim Feldwisch,et al.  Engineering of affibody molecules for therapy and diagnostics. , 2012, Methods in molecular biology.

[7]  M. Ozsahin,et al.  The epidermal growth factor receptor (EGFR) in head and neck cancer: its role and treatment implications , 2006, Radiation oncology.

[8]  A. Vahrmeijer,et al.  Seeing the invisible during surgery , 2011, The British journal of surgery.

[9]  Eva M. Sevick-Muraca,et al.  Single-Dose Intravenous Toxicity Study of IRDye 800CW in Sprague-Dawley Rats , 2010, Molecular Imaging and Biology.

[10]  Eben L Rosenthal,et al.  In Vivo Detection of Head and Neck Cancer Orthotopic Xenografts by Immunofluorescence , 2006, The Laryngoscope.

[11]  Eva M. Sevick-Muraca,et al.  Single dose toxicity study of IRDye 800CW in Sprague-Dawley rats , 2010, BiOS.

[12]  E. Rosenthal,et al.  Use of Panitumumab-IRDye800 to Image Microscopic Head and Neck Cancer in an Orthotopic Surgical Model , 2012, Annals of Surgical Oncology.

[13]  M. Lubberink,et al.  Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [68Ga]ABY-025 Affibody PET/CT , 2016, Theranostics.

[14]  Fredrik Y Frejd,et al.  Affibody molecules: Engineered proteins for therapeutic, diagnostic and biotechnological applications , 2010, FEBS letters.

[15]  Vasilis Ntziachristos,et al.  Intraoperative Near-Infrared Fluorescence Tumor Imaging with Vascular Endothelial Growth Factor and Human Epidermal Growth Factor Receptor 2 Targeting Antibodies , 2011, The Journal of Nuclear Medicine.

[16]  Xiaoyuan Chen,et al.  Characterizing breast cancer xenograft epidermal growth factor receptor expression by using near-infrared optical imaging , 2009, Acta radiologica.

[17]  K. Paulsen,et al.  Glioblastoma multiforme treatment with clinical trials for surgical resection (aminolevulinic acid). , 2012, Neurosurgery clinics of North America.

[18]  Brian W. Pogue,et al.  Fluorescent Affibody Peptide Penetration in Glioma Margin Is Superior to Full Antibody , 2013, PloS one.

[19]  Eben L Rosenthal,et al.  Optical imaging predicts tumor response to anti-EGFR therapy , 2010, Cancer biology & therapy.

[20]  E. Rosenthal,et al.  Use of fluorescent labeled anti–epidermal growth factor receptor antibody to image head and neck squamous cell carcinoma xenografts , 2007, Molecular Cancer Therapeutics.

[21]  M. Lubberink,et al.  First-in-Human Molecular Imaging of HER2 Expression in Breast Cancer Metastases Using the 111In-ABY-025 Affibody Molecule , 2014, The Journal of Nuclear Medicine.

[22]  Keith D. Paulsen,et al.  δ-aminolevulinic acid-induced protoporphyrin IX concentration correlates with histopathologic markers of malignancy in human gliomas: the need for quantitative fluorescence-guided resection to identify regions of increasing malignancy. , 2011, Neuro-oncology.

[23]  N. Bressler,et al.  Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. , 1999, Archives of ophthalmology.

[24]  E. Johansson,et al.  Directed evolution to low nanomolar affinity of a tumor-targeting epidermal growth factor receptor-binding affibody molecule. , 2008, Journal of molecular biology.

[25]  Tristan Barrett,et al.  In vivo molecular imaging to diagnose and subtype tumors through receptor-targeted optically labeled monoclonal antibodies. , 2007, Neoplasia.

[26]  Brian W. Pogue,et al.  Fluorescent Affibody Molecule Administered In Vivo at a Microdose Level Labels EGFR Expressing Glioma Tumor Regions , 2016, Molecular Imaging and Biology.

[27]  Joshua S Richman,et al.  Safety and Tumor Specificity of Cetuximab-IRDye800 for Surgical Navigation in Head and Neck Cancer , 2015, Clinical Cancer Research.

[28]  E. Rosenthal,et al.  Preclinical Comparison of Near-Infrared-Labeled Cetuximab and Panitumumab for Optical Imaging of Head and Neck Squamous Cell Carcinoma , 2013, Molecular Imaging and Biology.

[29]  R Birngruber,et al.  Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of retreatments in a phase 1 and 2 study. , 1999, Archives of ophthalmology.

[30]  Brian W Pogue,et al.  Review of fluorescence guided surgery systems: identification of key performance capabilities beyond indocyanine green imaging , 2016, Journal of biomedical optics.

[31]  Hisataka Kobayashi,et al.  Cancer Cell-Selective In Vivo Near Infrared Photoimmunotherapy Targeting Specific Membrane Molecules , 2011, Nature Medicine.

[32]  V. Prasad,et al.  Molecular Imaging of HER2-Expressing Malignant Tumors in Breast Cancer Patients Using Synthetic 111In- or 68Ga-Labeled Affibody Molecules , 2010, Journal of Nuclear Medicine.

[33]  E. Rosenthal,et al.  Sensitivity and specificity of fluorescent immunoguided neoplasm detection in head and neck cancer xenografts. , 2007, Archives of otolaryngology--head & neck surgery.

[34]  L. Abrahmsén,et al.  Affibody molecules: potential for in vivo imaging of molecular targets for cancer therapy , 2007, Expert opinion on biological therapy.

[35]  R Birngruber,et al.  Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of a single treatment in a phase 1 and 2 study. , 1999, Archives of ophthalmology.

[36]  Herbert Stepp,et al.  5-Aminolevulinic Acid-derived Tumor Fluorescence: The Diagnostic Accuracy of Visible Fluorescence Qualities as Corroborated by Spectrometry and Histology and Postoperative Imaging , 2013, Neurosurgery.

[37]  Tianhong Dai,et al.  The Nuts and Bolts of Low-level Laser (Light) Therapy , 2011, Annals of Biomedical Engineering.

[38]  E. Rosenthal,et al.  Fluorescent labeled anti‐EGFR antibody for identification of regional and distant metastasis in a preclinical xenograft model , 2008, Head & neck.

[39]  A. Valentijn,et al.  Near-Infrared Fluorescence Imaging of Both Colorectal Cancer and Ureters Using a Low-Dose Integrin Targeted Probe , 2014, Annals of Surgical Oncology.

[40]  N. Temple,et al.  Reference values for young normal Sprague-Dawley rats: weight gain, hematology and clinical chemistry , 1996, Human & experimental toxicology.

[41]  Xiaoyao Fan,et al.  Coregistered fluorescence-enhanced tumor resection of malignant glioma: relationships between δ-aminolevulinic acid-induced protoporphyrin IX fluorescence, magnetic resonance imaging enhancement, and neuropathological parameters. Clinical article. , 2011, Journal of neurosurgery.